Cognitive state, substance use patterns and outcome after discharge from Kfar Izun, a unique rehabilitation facility

References

• Bar-Hamburger R. 2005. Experiencing, opinion and behavioral intentions about tourists’ (backpackers’) drug usage among students. http://www.izun.org.il/imageBank/pdf/rachel_bar2005.pdf. (origin in Hebrew)
   Google Scholar
• Tzadok D. 2005. Drug usage amongst backpackers- data and treatment options. The Knesset research and information center. http://www.izun.org.il/imageBank/articales/Samim.pdf. (origin in Hebrew)
   Google Scholar
• Rosca P, Spivak P, Goldman K, Austin O. 2019. Activity report of the Addiction Treatment Department in the Israeli Ministry of Health for 2018. https://www.health.gov.il/UnitsOffice/HD/MHealth/mental/addictions/Documents/mtl-addictions-2018.pdf. (origin in Hebrew)
   Google Scholar
• Frish O. 2008. Drug abusing backpackers and their treatment in Kfar-Izun. http://www.izun.org.il/News_and_Articles.htm. (origen in Hebrew)
   Google Scholar
• Ezrahi Y, Shabtai M, Roziner I, Yavelberg Y, Ovadia N, Maimon- Cohen D, Bar-Hamburger R. 2006. An evaluation research for Kfar Izun-2006. Israel Authority for Prevention of Violence, Alcohol and Drug Abuse. Doi: http://www.izun.org.il/imageBank/articales/2006.pdf.
   Google Scholar
• Nachamkin J. 2008. The psychiatric therapy fo drug abusing backpackers in Kfar Izun. http://www.izun.org.il/imageBank/pdf/article/nahamkin.pdf. (origin in Hebrew)
   Google Scholar
• Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9. doi:10.1111/j.1532-5415.2005.53221.x.
   PubMed Web of Science ®Google Scholar
• Kave G, Knafo-Noam A. Lifespan development of phonemic and semantic fluency: Universal increase, differential decrease. J Clin Exp Neuropsychol. 2015;37(7):751–63. doi:10.1080/13803395.2015.1065958.
   PubMed Web of Science ®Google Scholar
• Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA. 1983. Manual for the state-trait anxiety inventory. Palo Alto, CA: Consulting Psychologists Press.
   Google Scholar
• Chen G, Gully S, Eden D. Validation of a new General Self Efficacy Scale. Organ. Res. Methods. 2001;4(1):62–83. doi:10.1177/109442810141004.
   Web of Science ®Google Scholar
• Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. The Lancet. 2007;369(9566):1047–53. doi:10.1016/S0140-6736(07)60464-4.
   PubMed Web of Science ®Google Scholar
• Levine A, Clemenza K, Rynn M, Lieberman J. Evidence for the risks and consequences of adolescent cannabis exposure. J Am Acad Child Adolesc Psychiatry. 2017;56(3):214–25. doi:10.1016/j.jaac.2016.12.014.
   PubMed Web of Science ®Google Scholar
• Hadland SE, Harris SK. Youth marijuana use: state of the science for the practicing clinician. Curr Opin Pediatr. 2014;26(4):420–7. doi:10.1097/MOP.0000000000000114.
   PubMed Web of Science ®Google Scholar
• Pierre JM. Psychosis associated with medical marijuana: risk vs. benefits of medicinal cannabis use. Am J Psychiatry. 2010;167(5):598–9. doi:10.1176/appi.ajp.2010.09121762.
   PubMed Web of Science ®Google Scholar
• Gerdner EL. Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol Biochem Behav. 2005;81:263–84.
   PubMed Web of Science ®Google Scholar
• Piomelli D. More surprises lying ahead. The endocannabinoids keep us guessing. Neuropharmacology. 2014;76:228–34. doi:10.1016/j.neuropharm.2013.07.026.
   PubMed Web of Science ®Google Scholar
• Pertwee RG, Howlett AC, Abood ME, Alexander SPH, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, et al. International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev. 2010;62(4):588–631. doi:10.1124/pr.110.003004.
   PubMed Web of Science ®Google Scholar
• Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA. Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical Implications. Drug Alcohol Depend. 2014;144:12–41. doi:10.1016/j.drugalcdep.2014.08.005.
   PubMed Web of Science ®Google Scholar
• Crane NA, Schuster RM, Fusar-Poli P, Gonzalez R. Effects of cannabis on neurocognitive functioning: recent advances, neurodevelopmental influences, and sex differences. Neuropsychol Rev. 2013;23(2):117–37. doi:10.1007/s11065-012-9222-1.
   PubMed Web of Science ®Google Scholar
• Crean RD, Crane NA, Mason BJ. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions . J Addict Med. 2011;5(1):1–8. doi:10.1097/ADM.0b013e31820c23fa.
   PubMed Web of Science ®Google Scholar
• Ranganathan M, D’Souza DC. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl). 2006;188(4):425–44. doi:10.1007/s00213-006-0508-y.
   PubMed Web of Science ®Google Scholar
• Grant I, Gonzalez R, Carey CL, Natarajan L, Wolfson T. Nonacute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J Int Neuropsychol Soc. 2003;9(5):679–89. doi:10.1017/S1355617703950016.
   PubMed Web of Science ®Google Scholar
• Schreiner AM, Dunn ME. Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: a metaanalysis. Exp Clin Psychopharmacol. 2012;20(5):420–9. doi:10.1037/a0029117.
   PubMed Web of Science ®Google Scholar
• Lubman DI, Cheetham A, Yucel M. Cannabis and adolescent brain development. Pharmacol Ther. 2015;148:1–16. doi:10.1016/j.pharmthera.2014.11.009.
   PubMed Web of Science ®Google Scholar
• Baumeister D, Tojo LM, Tracy DK. Legal highs: staying on top of the flood of novel psychoactive substances. Ther Adv Psychopharmacol. 2015;5(2):97–132. doi:10.1177/2045125314559539.
   PubMed Web of Science ®Google Scholar
• Scott JC, Woods SP, Matt GE, Meyer RA, Heaton RK, Atkinson JH, Grant I. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev. 2007;17(3):275–97. doi:10.1007/s11065-007-9031-0.
   PubMed Web of Science ®Google Scholar
• Bramness JG, Rognli EB. Psychosis induced by amphetamines. Curr Opin Psychiatry. 2016;29(4):236–41. doi:10.1097/YCO.0000000000000254.
   PubMed Web of Science ®Google Scholar
• Van der Meer FJ, Meijer JH, Meijer CJ, Van den Brink W, Velthorst E. Cognitive functioning associated with stimulant use in patients with non-affective psychosis, their unaffected siblings and healthy controls. Psychol Med. 2014;44(9):1901–11. doi:10.1017/S0033291713002626.
   PubMed Web of Science ®Google Scholar
• Bramness JG, Gundersen OH, Guterstam J, Rognli EB, Konstenius M, Løberg EM, Medhus S, Tanum L, Franck J. Amphetamine-induced psychosis – a separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC Psychiatry. 2012;12:221doi:10.1186/1471-244X-12-221.
   PubMed Web of Science ®Google Scholar
• Chen CK, Lin SK, Chen YC, Huang MC, Chen TT, Ree SC, Wang LJ. Persistence of psychotic symptoms as an indicator of cognitive impairment in methamphetamine users. Drug Alcohol Depend. 2015;148:158–64. doi:10.1016/j.drugalcdep.2014.12.035.
   PubMed Web of Science ®Google Scholar
• Fassbender C, Lesh TA, Ursu S, Salo R. Reaction time variability and related brain activity in methamphetamine psychosis. Biol Psychiatry. 2015;77(5):465–74. doi:10.1016/j.biopsych.2014.07.028.
   PubMed Web of Science ®Google Scholar
• Potvin S, Stavro K, Rizkallah E, Pelletier J. Cocaine and cognition: a systematic quantitative review. J Addict Med. 2014;8(5):368–76. doi:10.1097/ADM.0000000000000066.
   PubMed Web of Science ®Google Scholar
• Parrott AC. Human psychobiology of MDMA or ‘Ecstasy’: an overview of 25 years of empirical research. Hum Psychopharmacol Clin Exp. 2013;28(4):289–307. doi:10.1002/hup.2318.
   PubMed Web of Science ®Google Scholar
• Liang HJ, Lau CG, Tang A, Chan F, Ungvari GS, Tang WK. Cognitive impairments in poly-drug ketamine users. Addict Behav. 2013;38(11):2661–6. doi:10.1016/j.addbeh.2013.06.017.
   PubMed Web of Science ®Google Scholar